NewVale Capital

NewVale Capital is a growth equity investment firm based in Boulder, Colorado, focusing on the services architecture of the life science industry. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that are helping to bring the next generation of medicines to patients. With nearly $200 million under management, NewVale Capital makes investments ranging from $10 million to $50 million in growth companies across the pharmaceutical value chain, including discovery, clinical, manufacturing, regulatory, and commercialization.

The firm's investment strategy targets services, software, and technologies that provide a proven return on investment for pharmaceutical customers, aiming to accelerate timelines, reduce costs, and improve quality. NewVale Capital's team comprises veteran life science investors, company builders, and pharmaceutical executives who bring decades of experience in the global pharmaceutical industry. The firm has completed several initial investments, including a $20 million growth financing to expand the availability of Aizon's machine learning software, a $45 million growth financing in Argonaut Manufacturing Services, and a $14 million growth financing to Beaconcure.

NewVale Capital's approach is to support the next generation of life science services companies by investing in the infrastructure that underpins the pharmaceutical industry. By focusing on services that enhance the efficiency and effectiveness of pharmaceutical operations, the firm aims to play a critical role in bringing new medicines to patients. The firm's commitment to this sector is underscored by its substantial fund size and strategic investments in key areas of the pharmaceutical value chain.